Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + azacitidine + venetoclax in relapsed/refractory AML (MAV)
ChiCTR2500109729Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Aug 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: Composite complete response rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
mitoxantroneazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500109729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109729.